*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| C860 - Extranodal NK/T-cell lymphoma, nasal type - as a primary diagnosis code | C860 - Extranodal NK/T-cell lymphoma, nasal type - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 7.15 | |
| Readmission Rate (%) | 45.39 | |
| Unplanned Readmission Rate (%) | NA | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 840: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|
| Total Hospitalizations at DRG | 29,081 |
| Total Hospitalizations with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | 12 |
| DRG Share of Total Hospitalizations | 0.09 |
| % of Total ICD C860 - Extranodal NK/T-cell lymphoma, nasal type in DRG | 29.27 |
| Avg LOS at DRG | 9.8 |
| Avg LOS with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | 12.33 |
| Readmission Rate at DRG | 37.3 |
| Readmission Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA |
| Unplanned Readmission Rate at DRG | 22.57 |
| Unplanned Readmission Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA |
| Total Medicare payments at DRG | $683,745,757 |
| Total Medicare payments with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $349,971 |
| Total Medicare payment per Day at DRG | $2,399 |
| Total Medicare payment per Day with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $2,365 |
| Total Medicare payment per Hospitalization at DRG | $23,512 |
| Total Medicare payment per Hospitalization with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $29,164 |
| Total Medicare Charges at DRG | $3,049,100,784 |
| Total Medicare Charges with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $1,588,341 |
| Avg Charges at DRG | $104,849 |
| Avg Charges with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $132,362 |
| Mortality Rate at DRG | 13.07 |
| Mortality Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA |
| SNF Discharge Rate at DRG | 16.93 |
| SNF Discharge Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA |
| Home Discharge Rate at DRG | 29.4 |
| Home Discharge Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 840: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|
| Total Hospitalizations at DRG | 45,065 | |||
| Total Hospitalizations with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | 38 | |||
| DRG Share of Total Hospitalizations | 0.14 | |||
| % of Total ICD C860 - Extranodal NK/T-cell lymphoma, nasal type in DRG | 22.35 | |||
| Avg LOS at DRG | 4.03 | |||
| Avg LOS with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | 4.16 | |||
| Readmission Rate at DRG | 66.75 | |||
| Readmission Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | 63.16 | |||
| Unplanned Readmission Rate at DRG | 10.94 | |||
| Unplanned Readmission Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA | |||
| Total Medicare payments at DRG | $438,494,977 | |||
| Total Medicare payments with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $435,177 | |||
| Total Medicare payment per Day at DRG | $2,416 | |||
| Total Medicare payment per Day with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $2,754 | |||
| Total Medicare payment per Hospitalization at DRG | $9,730 | |||
| Total Medicare payment per Hospitalization with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $11,452 | |||
| Total Medicare Charges at DRG | $2,145,591,374 | |||
| Total Medicare Charges with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $1,679,406 | |||
| Avg Charges at DRG | $47,611 | |||
| Avg Charges with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | $44,195 | |||
| Mortality Rate at DRG | 0.08 | |||
| Mortality Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA | |||
| SNF Discharge Rate at DRG | 4.35 | |||
| SNF Discharge Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | NA | |||
| Home Discharge Rate at DRG | 81.76 | |||
| Home Discharge Rate with ICD C860 - Extranodal NK/T-cell lymphoma, nasal type | 94.74 |